With modern therapies for heart failure (HF) with reduced ejection fraction (HFrEF), some patients can improve their cardiac function during treatment. But despite this improvement in the ability of their hearts to pump, ...
Dec 15, 2022
0
8
UCLA researchers have found that the hormone estrogen may help reverse advanced pulmonary hypertension, a rare and serious condition that affects 2 to 3 million individuals in the U.S., mostly women, and can lead to heart ...
Sep 15, 2011
0
0
Serelaxin may be more effective for relieving dyspnea in heart failure with preserved ejection fraction (HFpEF) than reduced (HFrEF) during the first 24 hours, according to results from RELAX-AHF presented in today's late ...
May 26, 2013
0
0
Dapagliflozin reduces the risk for worsening heart failure or cardiovascular death, regardless of frailty status, according to a study published online April 26 in the Annals of Internal Medicine.
Apr 26, 2022
0
2
When a patient is experiencing heart failure, a leading cause of death worldwide, they begin to lose healthy and functioning cardiac cells. Heart failure causes these once-flexible cells to develop into fibrotic cells that ...
May 16, 2024
0
6
Johns Hopkins researchers have identified a new way to predict which heart failure patients are likely to see their condition get worse and which ones have a better prognosis. Their study is one of the first to show that ...
Dec 11, 2013
0
0
(HealthDay)—Glaucoma may be associated with lower fractional anisotropy in the optic radiations, forceps major, and corpus callosum, possibly as a result of white matter degeneration, according to a study published online ...
May 2, 2016
0
12
The cardiovascular benefits of the diabetes drug dapagliflozin extend across a wide spectrum of patients and are especially pronounced in those with reduced ejection fraction, a measure of the heart's pumping ability indicative ...
Mar 18, 2019
0
4
Detection of midwall fibrosis (the presence of scar tissue in the middle of the heart muscle wall) via magnetic resonance imaging among patients with nonischemic dilated cardiomyopathy (a condition affecting the heart muscle) ...
Mar 5, 2013
0
0
Sacubitril-valsartan is reasonably cost effective compared to widely-used therapies for reducing mortality and morbidity in patients with reduced ejection fraction heart failure. The findings are published in Annals of Internal ...
Aug 29, 2016
0
0
